Dr. Mannick is Chief Medical Officer of resTORbio, a biotech company that was spun-out of Novartis and targets pathways regulating aging to treat aging-related conditions.
Prior to joining resTORbio, Dr. Mannick was an Executive Director in the New Indications Discovery Unit at Novartis Institutes of Biomedical Research. Prior to joining Novartis, Dr. Mannick was a faculty member at Harvard Medical School and University of Massachusetts Medical School. Her NIH-sponsored laboratory focused on the role of protein S-nitrosylation in physiology and pathophysiology.
Dr. Mannick received her A.B. from Harvard College and her M.D. from Harvard Medical School. She completed her residency in Internal Medicine at Brigham and Women’s Hospital and an Infectious Disease fellowship as part of the Harvard Combined Infectious Disease Program. She is board-certified in Internal Medicine and Infectious Diseases.